Medicare
Health Care
NEW BRIEF: U.S. Patients Could Save Up to $5.8 Billion Through Competition from Humira and Enbrel Biosimilars
Policies that promote biosimilar competition have the potential to save U.S. patients up to $5.8 billion collectively if biosimilars to Humira and Enbrel grow in market share, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market ...
Blog
Getting the Drug Spending Facts Right
In a typical rant, Senator Sanders claimed in a September 15th press release that “at a time when the drug companies are charging us by far the highest prices in the world, Congress must demand that Medicare negotiate prices with this extremely greedy and powerful industry.” The Senator clearly misunderstands ...
Commentary
Single-Payer Will Worsen Healthcare Workers’ Plight
Healthcare workers are exchanging scrubs and gloves for signs and megaphones. In what’s been called “Striketober,” frontline staff are walking out of hospitals, emergency rooms, and doctor’s offices to insist on better pay, benefits, and hours. Earlier this month, Kaiser Permanente workers in California voted to authorize a strike over ...
Commentary
Sally Pipes: Democrats’ Drug Pricing Reforms Aren’t What They Seem
As part of their spending bill, Congressional Democrats are advancing legislation that’ll empower Medicare to “negotiate” drug prices in the program’s Part B and Part D benefits. They insist this policy enjoys broad support among voters. But they’re misleading the public. What Democrats are proposing is in fact a sweeping ...
Drug Pricing
NEW BRIEF: Focus Groups Overwhelmingly Disapprove of Government “Negotiated” Drug Pricing
Today, the Pacific Research Institute published an issue brief revealing overwhelming public disapproval for Medicare reforms that Congress is considering as part of its $3.5 trillion spending bill. Click here to read the full issue brief, “Drug Pricing Proposals Threaten America’s Most Vulnerable Patients.” “It’s a relief that Americans oppose ...
Commentary
Democrats Have Built a Healthcare Agenda Around an Imaginary Crisis
Is America in the midst of a health insurance crisis? That’s the picture Democrats in Washington are painting. According to their narrative, health coverage is out of reach for a number of Americans. Only an aggressive — and exorbitantly expensive — effort to expand the number of people covered by taxpayer-funded insurance ...
Commentary
Mixed Messaging On Boosters Leaves Americans Dazed And Confused
The Food and Drug Administration recently revised its emergency use authorization for Pfizer-BioNTech’s COVID-19 vaccine by approving a booster shot for individuals 65 and older, immunocompromised adults, and people with a high risk of exposure to the virus at work. It’s an exciting development for the nearly 80% of vaccinated Americans who want a ...
Commentary
Bernie’s Not-So-Subtle Single-Payer Plot
Senator Bernie Sanders (I.,Vt.), America’s most prominent proponent of government-run health care, is once again leading the charge to move our country to a single-payer system. As chairman of the Senate Budget Committee, Sanders is pushing a $3.5 trillion budget plan that includes expansions of Medicare, Medicaid, and Obamacare. Some ...
Commentary
Democrats’ Misguided Plan to Expand Medicare Doesn’t Add Up
For weeks, congressional Democrats have been pushing to lower Medicare’s eligibility age from 65 to 60 as part of their $3.5 trillion spending bill. A new paper from the American Action Forum (AAF) by Christopher Holt and Stephen Parente reveals just how radical that change would be. Such an expansion of Medicare would cost ...
Commentary
The FDA’s waiting game is costing children’s lives
This week, Pfizer-BioNTech submitted data to the Food and Drug Administration demonstrating the safety and effectiveness of its COVID-19 vaccine in children ages 5 to 11. The duo is expected to apply for emergency-use authorization in the coming weeks. Federal regulators have promised they’ll “urgently” review the data. The FDA’s ...
NEW BRIEF: U.S. Patients Could Save Up to $5.8 Billion Through Competition from Humira and Enbrel Biosimilars
Policies that promote biosimilar competition have the potential to save U.S. patients up to $5.8 billion collectively if biosimilars to Humira and Enbrel grow in market share, finds a new brief released today by the Center for Medical Economics and Innovation at the nonpartisan Pacific Research Institute, a California-based, free-market ...
Getting the Drug Spending Facts Right
In a typical rant, Senator Sanders claimed in a September 15th press release that “at a time when the drug companies are charging us by far the highest prices in the world, Congress must demand that Medicare negotiate prices with this extremely greedy and powerful industry.” The Senator clearly misunderstands ...
Single-Payer Will Worsen Healthcare Workers’ Plight
Healthcare workers are exchanging scrubs and gloves for signs and megaphones. In what’s been called “Striketober,” frontline staff are walking out of hospitals, emergency rooms, and doctor’s offices to insist on better pay, benefits, and hours. Earlier this month, Kaiser Permanente workers in California voted to authorize a strike over ...
Sally Pipes: Democrats’ Drug Pricing Reforms Aren’t What They Seem
As part of their spending bill, Congressional Democrats are advancing legislation that’ll empower Medicare to “negotiate” drug prices in the program’s Part B and Part D benefits. They insist this policy enjoys broad support among voters. But they’re misleading the public. What Democrats are proposing is in fact a sweeping ...
NEW BRIEF: Focus Groups Overwhelmingly Disapprove of Government “Negotiated” Drug Pricing
Today, the Pacific Research Institute published an issue brief revealing overwhelming public disapproval for Medicare reforms that Congress is considering as part of its $3.5 trillion spending bill. Click here to read the full issue brief, “Drug Pricing Proposals Threaten America’s Most Vulnerable Patients.” “It’s a relief that Americans oppose ...
Democrats Have Built a Healthcare Agenda Around an Imaginary Crisis
Is America in the midst of a health insurance crisis? That’s the picture Democrats in Washington are painting. According to their narrative, health coverage is out of reach for a number of Americans. Only an aggressive — and exorbitantly expensive — effort to expand the number of people covered by taxpayer-funded insurance ...
Mixed Messaging On Boosters Leaves Americans Dazed And Confused
The Food and Drug Administration recently revised its emergency use authorization for Pfizer-BioNTech’s COVID-19 vaccine by approving a booster shot for individuals 65 and older, immunocompromised adults, and people with a high risk of exposure to the virus at work. It’s an exciting development for the nearly 80% of vaccinated Americans who want a ...
Bernie’s Not-So-Subtle Single-Payer Plot
Senator Bernie Sanders (I.,Vt.), America’s most prominent proponent of government-run health care, is once again leading the charge to move our country to a single-payer system. As chairman of the Senate Budget Committee, Sanders is pushing a $3.5 trillion budget plan that includes expansions of Medicare, Medicaid, and Obamacare. Some ...
Democrats’ Misguided Plan to Expand Medicare Doesn’t Add Up
For weeks, congressional Democrats have been pushing to lower Medicare’s eligibility age from 65 to 60 as part of their $3.5 trillion spending bill. A new paper from the American Action Forum (AAF) by Christopher Holt and Stephen Parente reveals just how radical that change would be. Such an expansion of Medicare would cost ...
The FDA’s waiting game is costing children’s lives
This week, Pfizer-BioNTech submitted data to the Food and Drug Administration demonstrating the safety and effectiveness of its COVID-19 vaccine in children ages 5 to 11. The duo is expected to apply for emergency-use authorization in the coming weeks. Federal regulators have promised they’ll “urgently” review the data. The FDA’s ...
